OTC醫藥品產業：G8市場的產業指南 是由出版商MarketLine在2010年11月所出版的。
這份英文市場調查報告書包含Pages: 302 價格從美金1495起跳。
Abstract
Datamonitor' s OTC Pharmaceuticals - Global Group of Eight (G8) Industry Guide
is an essential resource for top-level data and analysis covering the OTC
Pharmaceuticals industry in each of the G8 (United States, Canada, Germany,
France, United Kingdom, Italy, Russia and Japan) countries. The report
includes easily comparable data on market value, volume, segmentation and
market share, plus full five year market forecasts. It examines future
problems, innovations and potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and
segmentation
* Provides textual analysis of the industry' s prospects, competitive
landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and
scorecards
* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and
Japan, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The G8 OTC Pharmaceuticals market grew by 2.7% between 2005 and 2009 to reach
a value of $68999.2 billion
In 2014, the market is forecast to have a value of $77727.6 billion, an
increase of 2.4% from 2009.
The US is the world’s largest market and generates 39.9% of global
revenues in 2009.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional
medicines, cough and cold preparations (tablets, mixtures, lozenges, topical
remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals,
single vitamins, tonics, cod liver oil), indigestion preparations (tablets,
powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other
analgesics), and medicated skin products (anti-bacteria’s, acne
treatments, anti-fungal, disinfectants and other), topical OTC medicines
(anesthetic products, anti-itch products, antibiotic creams/gels), plasters &
bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze,
liquid bandages and other tape or bandage), first aid kits and other
(anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and
motion sickness).
Table of Contents
TABLE OF CONTENTS
ABOUT DATAMONITOR
INTRODUCTION
What is this report about?
Who is the target reader?
How to use this report
Definitions
GROUP OF EIGHT (G8) OTC PHARMACEUTICALS INDUSTRY OUTLOOK
OTC PHARMACEUTICALS IN CANADA
Market overview
Market value
Market segmentation
Market segmentation I
Market share
Five forces analysis
Market Forecasts
Leading companies
Market distribution
Macroeconomic indicators
OTC PHARMACEUTICALS IN FRANCE
Market overview
Market value
Market segmentation
Market segmentation I
Market share
Five forces analysis
Market Forecasts
Leading companies
Market distribution
Macroeconomic indicators
OTC PHARMACEUTICALS IN GERMANY
Market overview
Market value
Market segmentation
Market segmentation I
Market share
Five forces analysis
Market Forecasts
Leading companies
Market distribution
Macroeconomic indicators
OTC PHARMACEUTICALS IN ITALY
Market overview
Market value
Market segmentation
Market segmentation I
Market share
Five forces analysis
Market Forecasts
Leading companies
Market distribution
Macroeconomic indicators
OTC PHARMACEUTICALS IN JAPAN
Market overview
Market value
Market segmentation
Market segmentation I
Market share
Five forces analysis
Market Forecasts
Leading companies
Market distribution
Macroeconomic indicators
OTC PHARMACEUTICALS IN RUSSIA
Market overview
Market value
Market segmentation
Market segmentation I
Market share
Five forces analysis
Market Forecasts
Leading companies
Market distribution
Macroeconomic indicators
OTC PHARMACEUTICALS IN THE UNITED KINGDOM
Market overview
Market value
Market segmentation
Market segmentation I
Market share
Five forces analysis
Market Forecasts
Leading companies
Market distribution
Macroeconomic indicators
OTC PHARMACEUTICALS IN THE UNITED STATES
Market overview
Market value
Market segmentation
Market segmentation I
Market share
Five forces analysis
Market Forecasts
Leading companies
Market distribution
Macroeconomic indicators
APPENDIX
Data Research Methodology 302
LIST OF TABLES
Table 1: G8 otc pharmaceuticals industry, revenue($m), 2005-14
Table 2: G8 OTC pharmaceuticals industry, revenue by country ($m),
2005-09
Table 3: G8 OTC pharmaceuticals industry forecast, revenue by country ($m),
2009-14
Table 4: Canada otc pharmaceuticals market value: $ million, 2005-09
Table 5: Canada otc pharmaceuticals Market segmentation I:% share, by value,
2009
Table 6: Canada otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 7: Canada otc pharmaceuticals market share: % share, by value, 2009
Table 8: Canada OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 9: Johnson & Johnson: key facts
Table 10: Johnson & Johnson: key financials ($
Table 11: Johnson & Johnson: key financial ratios
Table 12: GlaxoSmithKline Plc: key facts
Table 13: GlaxoSmithKline Plc: key financials ($
Table 14: GlaxoSmithKline Plc: key financials (£)
Table 15: GlaxoSmithKline Plc: key financial ratios
Table 16: Jamieson Laboratories: key facts
Table 17: Canada otc pharmaceuticals market distribution: % share, by value,
2009
Table 18: Canada size of population (million), 2005-09
Table 19: Canada gdp (constant 2000 prices, $ billion), 2005-09
Table 20: Canada gdp (current prices, $ billion), 2005-09
Table 21: Canada inflation, 2005-09
Table 22: Canada consumer price index (absolute), 2005-09
Table 23: Canada exchange rate, 2005-09
Table 24: France otc pharmaceuticals market value: $ million, 2005-09
Table 25: France otc pharmaceuticals Market segmentation I:% share, by value,
2009
Table 26: France otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 27: France otc pharmaceuticals market share: % share, by value, 2009
Table 28: France OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 29: Procter & Gamble Company, The: key facts
Table 30: Procter & Gamble Company, The: key financials ($
Table 31: Procter & Gamble Company, The: key financial ratios
Table 32: Sanofi-Aventis: key facts
Table 33: Sanofi-Aventis: key financials ($
Table 34: Sanofi-Aventis: key financials (€)
Table 35: Sanofi-Aventis: key financial ratios
Table 36: Reckitt Benckiser Plc: key facts
Table 37: Reckitt Benckiser Plc: key financials ($
Table 38: Reckitt Benckiser Plc: key financials (£)
Table 39: Reckitt Benckiser Plc: key financial ratios
Table 40: France otc pharmaceuticals market distribution: % share, by value,
2009
Table 41: France size of population (million), 2005-09
Table 42: France gdp (constant 2000 prices, $ billion), 2005-09
Table 43: France gdp (current prices, $ billion), 2005-09
Table 44: France inflation, 2005-09
Table 45: France consumer price index (absolute), 2005-09
Table 46: France exchange rate, 2005-09
Table 47: Germany otc pharmaceuticals market value: $ million, 2005-09
Table 48: Germany otc pharmaceuticals Market segmentation I:% share, by
value, 2009
Table 49: Germany otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 50: Germany otc pharmaceuticals market share: % share, by value, 2009
Table 51: Germany OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 52: Johnson & Johnson: key facts
Table 53: Johnson & Johnson: key financials ($
Table 54: Johnson & Johnson: key financial ratios
Table 55: Bayer AG: key facts
Table 56: Bayer AG: key financials ($
Table 57: Bayer AG: key financials (€)
Table 58: Bayer AG: key financial ratios
Table 59: GlaxoSmithKline Plc: key facts
Table 60: GlaxoSmithKline Plc: key financials ($
Table 61: GlaxoSmithKline Plc: key financials (£)
Table 62: GlaxoSmithKline Plc: key financial ratios
Table 63: Germany otc pharmaceuticals market distribution: % share, by value,
2009
Table 64: Germany size of population (million), 2005-09
Table 65: Germany gdp (constant 2000 prices, $ billion), 2005-09
Table 66: Germany gdp (current prices, $ billion), 2005-09
Table 67: Germany inflation, 2005-09
Table 68: Germany consumer price index (absolute), 2005-09
Table 69: Germany exchange rate, 2005-09
Table 70: Italy otc pharmaceuticals market value: $ million, 2005-09
Table 71: Italy otc pharmaceuticals Market segmentation I:% share, by value,
2009
Table 72: Italy otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 73: Italy otc pharmaceuticals market share: % share, by value, 2009
Table 74: Italy OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 75: Bayer AG: key facts
Table 76: Bayer AG: key financials ($
Table 77: Bayer AG: key financials (€)
Table 78: Bayer AG: key financial ratios
Table 79: GlaxoSmithKline Plc: key facts
Table 80: GlaxoSmithKline Plc: key financials ($
Table 81: GlaxoSmithKline Plc: key financials (£)
Table 82: GlaxoSmithKline Plc: key financial ratios
Table 83: Johnson & Johnson: key facts
Table 84: Johnson & Johnson: key financials ($
Table 85: Johnson & Johnson: key financial ratios
Table 86: Italy otc pharmaceuticals market distribution: % share, by value,
2009
Table 87: Italy size of population (million), 2005-09
Table 88: Italy gdp (constant 2000 prices, $ billion), 2005-09
Table 89: Italy gdp (current prices, $ billion), 2005-09
Table 90: Italy inflation, 2005-09
Table 91: Italy consumer price index (absolute), 2005-09
Table 92: Italy exchange rate, 2005-09
Table 93: Japan otc pharmaceuticals market value: $ million, 2005-09
Table 94: Japan otc pharmaceuticals Market segmentation I:% share, by value,
2009
Table 95: Japan otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 96: Japan otc pharmaceuticals market share: % share, by value, 2009
Table 97: Japan OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 98: Johnson & Johnson: key facts
Table 99: Johnson & Johnson: key financials ($
Table 100: Johnson & Johnson: key financial ratios
Table 101: Kracie Holdings, Ltd: key facts
Table 102: Novartis AG: key facts
Table 103: Novartis AG: key financials ($
Table 104: Novartis AG: key financial ratios
Table 105: Japan otc pharmaceuticals market distribution: % share, by value,
2009
Table 106: Japan size of population (million), 2005-09
Table 107: Japan gdp (constant 2000 prices, $ billion), 2005-09
Table 108: Japan gdp (current prices, $ billion), 2005-09
Table 109: Japan inflation, 2005-09
Table 110: Japan consumer price index (absolute), 2005-09
Table 111: Japan exchange rate, 2005-09
Table 112: Russia otc pharmaceuticals market value: $ million, 2005-09
Table 113: Russia otc pharmaceuticals Market segmentation I:% share, by
value, 2009
Table 114: Russia otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 115: Russia otc pharmaceuticals market share: % share, by value, 2009
Table 116: Russia OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 117: Ranbaxy Laboratories Limited: key facts
Table 118: Ranbaxy Laboratories Limited: key financials ($
Table 119: Ranbaxy Laboratories Limited: key financials (Rs.)
Table 120: Ranbaxy Laboratories Limited: key financial ratios
Table 121: Johnson & Johnson: key facts
Table 122: Johnson & Johnson: key financials ($
Table 123: Johnson & Johnson: key financial ratios
Table 124: Krka: key facts
Table 125: Krka: key financials ($
Table 126: Krka: key financials (€)
Table 127: Krka: key financial ratios
Table 128: Russia otc pharmaceuticals market distribution: % share, by value,
2009
Table 129: Russia size of population (million), 2005-09
Table 130: Russia gdp (constant 2000 prices, $ billion), 2005-09
Table 131: Russia gdp (current prices, $ billion), 2005-09
Table 132: Russia inflation, 2005-09
Table 133: Russia consumer price index (absolute), 2005-09
Table 134: Russia exchange rate, 2005-09
Table 135: United Kingdom otc pharmaceuticals market value: $ million,
2005-09
Table 136: United Kingdom otc pharmaceuticals Market segmentation I:% share,
by value, 2009
Table 137: United Kingdom otc pharmaceuticals Market segmentation II: %
share, by value, 2009
Table 138: United Kingdom otc pharmaceuticals market share: % share, by
value, 2009
Table 139: United Kingdom OTC pharmaceuticals market value forecast: $
million, 2009-14
Table 140: Reckitt Benckiser Plc: key facts
Table 141: Reckitt Benckiser Plc: key financials ($
Table 142: Reckitt Benckiser Plc: key financials (£)
Table 143: Reckitt Benckiser Plc: key financial ratios
Table 144: Johnson & Johnson: key facts
Table 145: Johnson & Johnson: key financials ($
Table 146: Johnson & Johnson: key financial ratios
Table 147: GlaxoSmithKline Plc: key facts
Table 148: GlaxoSmithKline Plc: key financials ($
Table 149: GlaxoSmithKline Plc: key financials (£)
Table 150: GlaxoSmithKline Plc: key financial ratios
Table 151: United Kingdom otc pharmaceuticals market distribution: % share,
by value, 2009
Table 152: United Kingdom size of population (million), 2005-09
Table 153: United Kingdom gdp (constant 2000 prices, $ billion),
2005-09
Table 154: United Kingdom gdp (current prices, $ billion), 2005-09
Table 155: United Kingdom inflation, 2005-09
Table 156: United Kingdom consumer price index (absolute), 2005-09
Table 157: United Kingdom exchange rate, 2005-09
Table 158: United States otc pharmaceuticals market value: $ million,
2005-09
Table 159: United States otc pharmaceuticals Market segmentation I:% share,
by value, 2009
Table 160: United States otc pharmaceuticals Market segmentation II: % share,
by value, 2009
Table 161: United States otc pharmaceuticals market share: % share, by value,
2009
Table 162: United States OTC pharmaceuticals market value forecast: $
million, 2009-14
Table 163: Johnson & Johnson: key facts
Table 164: Johnson & Johnson: key financials ($
Table 165: Johnson & Johnson: key financial ratios
Table 166: Pfizer: key facts
Table 167: Pfizer: key financials ($
Table 168: Pfizer: key financial ratios
Table 169: Procter & Gamble Company, The: key facts
Table 170: Procter & Gamble Company, The: key financials ($
Table 171: Procter & Gamble Company, The: key financial ratios
Table 172: United States otc pharmaceuticals market distribution: % share, by
value, 2009
Table 173: United States size of population (million), 2005-09
Table 174: United States gdp (constant 2000 prices, $ billion), 2005-09
Table 175: United States gdp (current prices, $ billion), 2005-09
Table 176: United States inflation, 2005-09
Table 177: United States consumer price index (absolute), 2005-09
Table 178: United States exchange rate, 2005-09 301
LIST OF FIGURES
Figure 1: G8 otc pharmaceuticals industry, revenue($m), 2005-14
Figure 2: G8 OTC Pharmaceuticals industry, revenue by country (%), 2009
Figure 3: G8 OTC pharmaceuticals industry, revenue by country ($m),
2005-09
Figure 4: G8 OTC pharmaceuticals industry forecast, revenue by country ($m),
2009-14
Figure 5: Canada otc pharmaceuticals market value: $ million, 2005-09
Figure 6: Canada otc pharmaceuticals Market segmentation I:% share, by value,
2009
Figure 7: Canada otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 8: Canada otc pharmaceuticals market share: % share, by value, 2009
Figure 9: Forces driving competition in the otc pharmaceuticals market in
Canada, 2009
Figure 10: Drivers of buyer power in the otc pharmaceuticals market in
Canada, 2009
Figure 11: Drivers of supplier power in the otc pharmaceuticals market in
Canada, 2009
Figure 12: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Canada, 2009
Figure 13: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Canada, 2009
Figure 14: Drivers of degree of rivalry in the otc pharmaceuticals market in
Canada, 2009
Figure 15: Canada OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 16: Johnson & Johnson: revenues & profitability
Figure 17: Johnson & Johnson: assets & liabilities
Figure 18: GlaxoSmithKline Plc: revenues & profitability
Figure 19: GlaxoSmithKline Plc: assets & liabilities
Figure 20: Canada otc pharmaceuticals market distribution: % share, by value,
2009
Figure 21: France otc pharmaceuticals market value: $ million, 2005-09
Figure 22: France otc pharmaceuticals Market segmentation I:% share, by
value, 2009
Figure 23: France otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 24: France otc pharmaceuticals market share: % share, by value, 2009
Figure 25: Forces driving competition in the otc pharmaceuticals market in
France, 2009
Figure 26: Drivers of buyer power in the otc pharmaceuticals market in
France, 2009
Figure 27: Drivers of supplier power in the otc pharmaceuticals market in
France, 2009
Figure 28: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in France, 2009
Figure 29: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in France, 2009
Figure 30: Drivers of degree of rivalry in the otc pharmaceuticals market in
France, 2009
Figure 31: France OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 32: Procter & Gamble Company, The: revenues & profitability
Figure 33: Procter & Gamble Company, The: assets & liabilities
Figure 34: Sanofi-Aventis: revenues & profitability
Figure 35: Sanofi-Aventis: assets & liabilities
Figure 36: Reckitt Benckiser Plc: revenues & profitability
Figure 37: Reckitt Benckiser Plc: assets & liabilities
Figure 38: France otc pharmaceuticals market distribution: % share, by value,
2009
Figure 39: Germany otc pharmaceuticals market value: $ million, 2005-09
Figure 40: Germany otc pharmaceuticals Market segmentation I:% share, by
value, 2009
Figure 41: Germany otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 42: Germany otc pharmaceuticals market share: % share, by value, 2009
Figure 43: Forces driving competition in the otc pharmaceuticals market in
Germany, 2009
Figure 44: Drivers of buyer power in the otc pharmaceuticals market in
Germany, 2009
Figure 45: Drivers of supplier power in the otc pharmaceuticals market in
Germany, 2009
Figure 46: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Germany, 2009
Figure 47: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Germany, 2009
Figure 48: Drivers of degree of rivalry in the otc pharmaceuticals market in
Germany, 2009
Figure 49: Germany OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 50: Johnson & Johnson: revenues & profitability
Figure 51: Johnson & Johnson: assets & liabilities
Figure 52: Bayer AG: revenues & profitability
Figure 53: Bayer AG: assets & liabilities
Figure 54: GlaxoSmithKline Plc: revenues & profitability
Figure 55: GlaxoSmithKline Plc: assets & liabilities
Figure 56: Germany otc pharmaceuticals market distribution: % share, by
value, 2009
Figure 57: Italy otc pharmaceuticals market value: $ million, 2005-09
Figure 58: Italy otc pharmaceuticals Market segmentation I:% share, by value,
2009
Figure 59: Italy otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 60: Italy otc pharmaceuticals market share: % share, by value, 2009
Figure 61: Forces driving competition in the otc pharmaceuticals market in
Italy, 2009
Figure 62: Drivers of buyer power in the otc pharmaceuticals market in Italy,
2009
Figure 63: Drivers of supplier power in the otc pharmaceuticals market in
Italy, 2009
Figure 64: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Italy, 2009
Figure 65: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Italy, 2009
Figure 66: Drivers of degree of rivalry in the otc pharmaceuticals market in
Italy, 2009
Figure 67: Italy OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 68: Bayer AG: revenues & profitability
Figure 69: Bayer AG: assets & liabilities
Figure 70: GlaxoSmithKline Plc: revenues & profitability
Figure 71: GlaxoSmithKline Plc: assets & liabilities
Figure 72: Johnson & Johnson: revenues & profitability
Figure 73: Johnson & Johnson: assets & liabilities
Figure 74: Italy otc pharmaceuticals market distribution: % share, by value,
2009
Figure 75: Japan otc pharmaceuticals market value: $ million, 2005-09
Figure 76: Japan otc pharmaceuticals Market segmentation I:% share, by value,
2009
Figure 77: Japan otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 78: Japan otc pharmaceuticals market share: % share, by value, 2009
Figure 79: Forces driving competition in the otc pharmaceuticals market in
Japan, 2009
Figure 80: Drivers of buyer power in the otc pharmaceuticals market in Japan,
2009
Figure 81: Drivers of supplier power in the otc pharmaceuticals market in
Japan, 2009
Figure 82: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Japan, 2009
Figure 83: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Japan, 2009
Figure 84: Drivers of degree of rivalry in the otc pharmaceuticals market in
Japan, 2009
Figure 85: Japan OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 86: Johnson & Johnson: revenues & profitability
Figure 87: Johnson & Johnson: assets & liabilities
Figure 88: Novartis AG: revenues & profitability
Figure 89: Novartis AG: assets & liabilities
Figure 90: Japan otc pharmaceuticals market distribution: % share, by value,
2009
Figure 91: Russia otc pharmaceuticals market value: $ million, 2005-09
Figure 92: Russia otc pharmaceuticals Market segmentation I:% share, by
value, 2009
Figure 93: Russia otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 94: Russia otc pharmaceuticals market share: % share, by value, 2009
Figure 95: Forces driving competition in the otc pharmaceuticals market in
Russia, 2009
Figure 96: Drivers of buyer power in the otc pharmaceuticals market in
Russia, 2009
Figure 97: Drivers of supplier power in the otc pharmaceuticals market in
Russia, 2009
Figure 98: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Russia, 2009
Figure 99: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Russia, 2009
Figure 100: Drivers of degree of rivalry in the otc pharmaceuticals market in
Russia, 2009
Figure 101: Russia OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 102: Ranbaxy Laboratories Limited: revenues & profitability
Figure 103: Ranbaxy Laboratories Limited: assets & liabilities
Figure 104: Johnson & Johnson: revenues & profitability
Figure 105: Johnson & Johnson: assets & liabilities
Figure 106: Krka: revenues & profitability
Figure 107: Krka: assets & liabilities
Figure 108: Russia otc pharmaceuticals market distribution: % share, by
value, 2009
Figure 109: United Kingdom otc pharmaceuticals market value: $ million,
2005-09
Figure 110: United Kingdom otc pharmaceuticals Market segmentation I:% share,
by value, 2009
Figure 111: United Kingdom otc pharmaceuticals Market segmentation II: %
share, by value, 2009
Figure 112: United Kingdom otc pharmaceuticals market share: % share, by
value, 2009
Figure 113: Forces driving competition in the otc pharmaceuticals market in
the United Kingdom, 2009
Figure 114: Drivers of buyer power in the otc pharmaceuticals market in the
United Kingdom, 2009
Figure 115: Drivers of supplier power in the otc pharmaceuticals market in
the United Kingdom, 2009
Figure 116: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in the United Kingdom, 2009
Figure 117: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in the United Kingdom, 2009
Figure 118: Drivers of degree of rivalry in the otc pharmaceuticals market in
the United Kingdom, 2009
Figure 119: United Kingdom OTC pharmaceuticals market value forecast: $
million, 2009-14
Figure 120: Reckitt Benckiser Plc: revenues & profitability
Figure 121: Reckitt Benckiser Plc: assets & liabilities
Figure 122: Johnson & Johnson: revenues & profitability
Figure 123: Johnson & Johnson: assets & liabilities
Figure 124: GlaxoSmithKline Plc: revenues & profitability
Figure 125: GlaxoSmithKline Plc: assets & liabilities
Figure 126: United Kingdom otc pharmaceuticals market distribution: % share,
by value, 2009
Figure 127: United States otc pharmaceuticals market value: $ million,
2005-09
Figure 128: United States otc pharmaceuticals Market segmentation I:% share,
by value, 2009
Figure 129: United States otc pharmaceuticals Market segmentation II: %
share, by value, 2009
Figure 130: United States otc pharmaceuticals market share: % share, by
value, 2009
Figure 131: Forces driving competition in the otc pharmaceuticals market in
the United States, 2009
Figure 132: Drivers of buyer power in the otc pharmaceuticals market in the
United States, 2009
Figure 133: Drivers of supplier power in the otc pharmaceuticals market in
the United States, 2009
Figure 134: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in the United States, 2009
Figure 135: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in the United States, 2009
Figure 136: Drivers of degree of rivalry in the otc pharmaceuticals market in
the United States, 2009
Figure 137: United States OTC pharmaceuticals market value forecast: $
million, 2009-14
Figure 138: Johnson & Johnson: revenues & profitability
Figure 139: Johnson & Johnson: assets & liabilities
Figure 140: Pfizer: revenues & profitability
Figure 141: Pfizer: assets & liabilities
Figure 142: Procter & Gamble Company, The: revenues & profitability
Figure 143: Procter & Gamble Company, The: assets & liabilities
Figure 144: United States otc pharmaceuticals market distribution: % share,
by value, 2009
